Introduction
von Willebrand factor (vWF) is important for platelet adhesion and subsequent thrombus formation, 1 therefore, a qualitative or quantitative change in plasma vWF is a predictive factor for cardiovascular disease or bleeding diathesis. 2 Whereas an elevated plasma level of vWF is associated with increased risk of venous thrombosis, coronary artery disease, and stroke, 3, 4, 5, 6 inherited or acquired vWF deficiency syndrome (von Willebrand disease, vWD) results in frequent hemorrhagic disorders. 7 Measurement of vWF continues to be the most important laboratory test for vWD diagnosis. 7 Type 3 vWD, the most severe form due to complete absence of vWF in all vascular compartments including plasma, endothelial cells, and platelets 8 is a lifethreatening condition due to major defects in coagulation and primary hemostasis.
vWF is stored in Weibel-Palade bodies (WPBs) 9 which are unique secretory granules in endothelial cells 10 which also contain P-selectin 11 and other pro-coagulation and proinflammatory factors. 12 vWF is also stored in and released from platelet α-granules during platelet activation. 13 Release of vWF from ECs is thought to be mediated by both constitutive (basal) and agonist-induced signaling pathways, whereas vWF secretion from platelet α -granules is entirely stimulus-induced. 14 Circulating vWF levels are likely maintained by basal secretion of vWF from ECs, and thus a change in this process would dramatically affect plasma vWF levels. 15 Delivery of EC-specific vWF to patients and mice with vWD is sufficient to correct defects in hemostasis 7, 13 whereas platelet-derived vWF only partially restores defects in thrombosis. 13 Exocytosis, mediated by fusion of secretory vesicles with the plasma membrane, 16 requires the ATP-ase N-ethylmaleimide-sensitive-fusion factor (NSF), soluble NSF attachment protein alpha (α-SNAP), and SNAP receptors (SNAREs). 14, 17 α -SNAP binding to the cisFor personal use only. on May 29, 2017 . by guest www.bloodjournal.org From SNARE complex in the fused membrane mediates recruitment of NSF that together promote exocytosis and SNARE disassembly.
14 Although this core secretory machinery is widely expressed, there is significant heterogeneity in the signaling mechanisms that control endothelial secretory granule exocytosis. 18 Activation of GPCRs and G protein α subunits (Gs, Gi and Gq/11) can stimulate secretory granule release. 19 Thrombin (enzyme IIa) produced during vascular injury activates the coagulation cascade and also potentiates vWF secretion via stimulation of protease activated receptor-1 (PAR1)-dependent signaling. 20, 21 The general mechanism by which G protein α subunits regulate exocytosis is not known, although it has been suggested G proteins mediate cell-type and compartment-specific functions and early transport events. 19 Direct G proteindependent regulation of the SNARE protein fusion machinery required for secretory granule exocytosis has been previously reported 22 . Distinct from their traditional plasma membrane localization, 23 heterotrimeric G proteins have been shown to shuttle rapidly between plasma membrane and intracellular membranes where they have distinct roles on specific organelles, including those in exocytotic pathways. 24 A yeast two-hybrid screen using activated Gα12 as bait identified α -SNAP, an intrinsic component of the endothelial exocytotic machinery, 14 as a potential binding partner for Gα12. 25 Thus, we reasoned that Gα12 may play an important role in promoting membrane trafficking and exocytosis in endothelial cells and assessed the role of Gα12/α-SNAP interactions as well as Gα12/13 and Gαq/11 signaling in basal and thrombininduced vWF secretion, primary hemostasis, and thrombosis. Collectively, our results describe a molecular mechanism of vWF release that is dependent on Gα12 and Gαq/11 signaling via RhoA-and Ca 2+ / α-SNAP-dependent mobilization and fusion of WPBs, with additional evidence implicating direct interaction of Gα12 with α -SNAP serves as a catalyst for basal vWF secretion.
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Material and Methods

An expanded Methods section is available in the online supplement.
Mouse monoclonal antibodies against guanine nucleotide G protein α subunits Gα12, Gα13 and Gαq/11 were generated as previously described. 26 Human plasma-derived vWF was purified as described. 1 Tamoxifen-inducible tie2-CreER T2 ;Gα13 flox/flox ;Gα12 -/-(endothelial cell-specific Gα13 knockout (EC-Gα13 -/-) in global Gα12 -/-background) and tamoxifen-inducible tie2-
-/-background) were as described. 27, 28 vWF secretion assay was as previously described. 29 Tail-snip blood loss was determined as described. 30, 31 Real-time intravital microscopy of cremaster muscle arteriole thrombus formation was performed as previously described. 32 Myc-tagged constitutively activated Gα12 Q229L mutant and Gα12 WT constructs bearing 'NAAIRS' cassette were as described. 33 Data are presented as mean ± SEM. Statistical significance was assessed by one-way ANOVA with Bonferoni post hoc testing; p < 0.05 was considered significant. All procedures on mice were approved by the Figure 1C) ). The accumulation of vWF in recirculating lung perfusate over time described a straight line in WT mice (secretion rate = 2.5 mU/mL/min). Intriguingly, baseline vWF values were significantly lower in Gα12
-/-mouse lungs ( Figure 1C ) (secretion rate = 0.6 ± 0.03 mU/mL/min).
To assess the mechanism of thrombin-induced vWF release from ECs via PAR-1 activation, we used the PAR-1 specific synthetic peptide TFLLR to stimulate lung ECs.
Addition of 30 µM TFLLR to the recirculating lung perfusate sharply increased vWF level in WT mice which peaked after 10-15 min and remained constant for up to 1h. The initial slope of the vWF secretion curve was used to estimate the rate of vWF release following addition of TFLLR, which was approximately 25 mU/mL/min in WT mouse lungs. In Gα12 -/-mouse lungs, TFLLR-induced vWF secretion was significantly reduced (3 mU/mL/min; Figure 1C ). Under these same conditions, basal vWF secretion in the pulmonary circulation of EC-Gαq -/-;Gα11 
Regulation of hemostasis and thrombosis by Gα12
In a previously published study performed using megakaryocyte-restricted-Gα12/13 double knockout mice, it was observed that Gα13-dependent signaling in platelets is important for hemostasis and thrombosis. 28 However, the molecular mechanisms and functional significance of endothelial cell Gα12 and Gα13 in primary hemostasis were not assessed. As a direct measurement of primary hemostasis, we determined blood loss after tail-snip in anesthetized EC-Gα13 -/-;Gα12 -/-vs. WT mice (n=3 male mice/group, age 8 weeks) as previously described. 31 Hb accumulation from the cut tail immersed in saline solution was measured every 5 min for 15 min. The induced hemorrhagic event was significantly prolonged in EC-Gα13
-/-;Gα12 -/-mice compared to WT mice (Figure 2A ). In addition, EC-Gα13 -/-;Gα12 -/-mice were prone to spontaneous hemorrhagic incidents in the abdominal cavity and recurrence of bleeding -/-mice, platelet thrombus formation was initiated at the site of arteriolar injury ( Figure   2B ). However, the platelet thrombus did not grow at the injury site in Gα12 -/-mice as compared with WT mice (Figure 2B-C) . From these results, we concluded that Gα12-dependent EC vWF secretion is required for hemostasis and thrombosis and focused on this mechanism in comparison to EC Gαq signaling in subsequent studies.
Potentiation of Gα12-dependent basal EC-vWF release by thrombin-stimulated Gαq/Gα11 and Gα12 regulated EC-vWF secretion in vitro
We next investigated the role of G protein signaling in basal vs. PAR1-stimulated vWF secretion from confluent, low passage, and serum-deprived HUVECs and HPAECs. Using a siRNA approach, G protein α subunits Gαq, Gα12 and Gα13 were depleted from HUVEC Figure 3A) , however, we observed no significant effect on basal or thrombin-induced vWF secretion ( Figure 3B ). These data suggest that Gα12 but not Gα13 mediates EC-specific basal as well as thrombin-induced vWF release from cultured HUVEC and HPAEC.
We next investigated the involvement of Gαq in the regulation of the vWF secretory pathway. Gαq siRNA resulted in nearly complete Gαq depletion while Gα12 protein level remained unchanged ( Figure 3A) . Following Gαq depletion, the amount of vWF released upon thrombin stimulation was reduced by 40% in HUVEC ( Figure 3B and Supplemental Figure   3B ) and 60% in HPAEC whereas basal vWF secretion was not affected ( Figure 3B and Supplemental Figure 3C ). These data suggest that Gαq is important in thrombin-evoked EC vWF secretion.
1
Role of NSF/αSNAP, p115RhoGEF and RhoA in basal vs. thrombin-induced vWF release N-Ethylmaleimide (NEM) is a well-known inhibitor of exocytosis in endothelial cells. 34 Consistent with the notion that WPB exocytosis requires NSF/α-SNAP 17 , addition of 1 mM NEM to the recirculating lung perfusion system for 1 min abolished vWF secretion (Supplemental Figure 4A) . To explore the role of α -SNAP in constitutive and thrombin-or calcium ionophore-induced vWF release from human endothelial cells, siRNA was used to deplete α-SNAP from HUVEC and then vWF was measured by ELISA as above. Cell lysates were also saved for Western blot analysis ( Figure 3C ). We observed that α -SNAP depletion completely blocked basal and thrombin-as well as calcium ionophore-induced vWF secretion ( Figure 3D and Supplemental Figure 4B ). These data demonstrate that α -SNAP is required for all forms of vWF secretion.
In p115 RhoGEF and RhoA siRNA-depleted HUVECs (Figure 3C ), thrombin-induced vWF secretion was reduced by 20-40% although basal vWF secretion was not affected ( Figure   3D ). Thus, Gα12-mediated basal vWF secretion occurs independently of the Rho pathway whereas receptor-mediated Gα12 and/or Gαq/11 signaling enhances vWF secretion via p115
RhoGEF and RhoA signaling.
siRNA-mediated Gα12 depletion blocks thrombin-induced WPB exocytosis in vitro
To distinguish whether the inhibitory effect of Gα12 depletion on vWF secretion is due to inhibition of vWF secretion as opposed to impaired vWF production or storage, we performed vWF immunostaining and confocal microscopy of control siRNA and Gα12 siRNA-treated
HUVECs in presence or absence of thrombin stimulation. As shown in Figure 4A , unstimulated HUVEC transfected with control or Gα12 siRNA both exhibited vWF-staining patterns 
Depletion of EC Gα12 impairs vWF-dependent platelet adhesion in vitro
Platelet adhesion is one of the earliest responses to vascular injury and is directly influenced by blood flow. 35 To elucidate the role of Gα12 signaling in vWF secretion and thrombosis evoked by shear stress, we used a functional flow-based assay and imaged platelet adhesion along secreted strands of vWF. 36 A shear rate of 600 s -1 (~6 dynes/cm 2 ) induced by a cone-plate rheometer was used to mimic physiologic arterial or arteriolar wall shear forces 37 and promote the formation of vWF strings emanating from cultured ECs (Supplemental Figure 5) .
Control siRNA or Gα12 siRNA-treated HUVECs were exposed to uniform and constant shear in presence or absence of washed platelets. Platelet adhesion/alignment on vWF 'strings' was assessed 5 minutes after shear initiation by fixation with 2% paraformaldehyde and
immunostaining with anti-vWF and anti-Gp1b antibodies. Representative confocal images ( Figure 4D ) and summarized data ( Figure 4E ) indicate that depletion of Gα12 impaired shearinduced platelet adhesion along vWF strings. Therefore, EC vWF secretion and subsequent formation of vWF filaments to which platelets adhere requires EC Gα12.
Activated Gα12 stimulates WPB exocytosis from HUVECs
To elucidate the role of Gα12 in WPBs exocytosis, HUVEC were transfected with constitutively-active GFP-tagged Gα12 Q229L mutant, GFP-tagged Gα12 
Gα12 modulation of α -SNAP regulates vWF exocytosis in vitro
We observed that α -SNAP siRNA blocks basal, thrombin-evoked, and Ca 2+ ionophore-induced secretion of vWF ( Figure 3D ; Supplemental Figure 4B ) indicating that α -SNAP-mediated fusion of WPBs is required for vWF secretion. We next explored the role of Gα12/αSNAP interactions in regulation of vWF secretion using a two-step experimental approach. First, we used a library of Gα12-substitution mutants 33 ( Figure 6A ) in which the primary sequence of For personal use only. on May 29, 2017 . by guest www.bloodjournal.org From
Discussion
Using a combination of several independent model and assay systems, including G protein deficient mice, blood loss measurement after tail-snip, cremaster arteriolar laser-injury thrombus formation, isolated buffer-perfused mouse lungs, and specific siRNA-depleted cultured human endothelial cells (ECs) derived from umbilical vein and pulmonary artery (HUVEC and HPAEC), we investigated the molecular mechanism of EC-specific vWF secretion.
Previous studies using megakariocyte-restricted-Gα12 and Gα13-deficient mice demonstrated that Gα13-dependent signaling regulates platelet aggregation, shape change, as well as U46619-and PAR4-induced P-selectin degranulation. 28 In contrast, the present study in
ECs indicates that Gα13 knock-down has no effect on basal or evoked vWF release. Rather, using a loss of function approach as well as exogenous expression of mutationally-activated Gα12, we observed that Gα12 mediates both basal (or constitutive-like, which maintains the circulating concentration of vWF) and thrombin-evoked (or regulated) vWF secretion (which results in the local release of vWF at the site of vascular injury).
We identified two independent mechanisms that may explain how Gα12 modulates both basal and evoked secretion of vWF from ECs. First, Gα12 interacts directly with α -SNAP and functions to facilitate WPB exocytosis at the plasma membrane. Second, Gα12 appears to be involved in the delivery of WPBs containing vWF to the plasma membrane. In eukaryotic cells,
Gα12 in its GTP-bound form is known to activate p115 RhoGEF and its downstream effector
RhoA leading to increased actin polymerization and actinomyosin cross-bridge cycling. 33 As recently described by Nightingale et al. (2011) , dynamic assembly and disassembly of actin rings at the base of WPBs promotes the translocation of WPBs to the plasma membrane and exocytosis of vWF once fused. 38 In support of this assertion, our studies suggest classical Gα12-For personal use only. on May 29, 2017 . by guest www.bloodjournal.org From dependent signaling via p115RhoGEF and RhoA activation may promote actin-dependent delivery of WPBs to the membrane independent of Gα12-mediated activation of the exocyst complex.
In cultured HUVEC and HPAEC, we observed impaired thrombin-evoked vWF secretion due to siRNA-mediated Gα12 and Gαq depletion, whereas only Gα12 deficiency abolished basal secretion. Thus, Gα12 and Gαq/11 signaling appears to be required for basal and/or evoked vWF secretion from mouse and human endothelial cells. HUVEC depleted of α -SNAP by specific siRNA downregulation were also unable to release vWF basally or in response to thrombin or calcium ionophore A23187. Therefore, Gα12 and α-SNAP are critical components of the vWF release mechanism, whereas Gαq/11 activation downstream of PAR-1 appears to be involved in potentiating vWF secretion. 
Consistent with in vitro
defects were shown to be due to impaired secretion and low plasma vWF level in absence of Gα12, rather than to abnormal vWF multimerization. vWF secretion has been described to occur via three pathways: constitutive, constitutivelike, and regulated, where only regulated secretion requires agonist stimulation. 20, 39, 40 Resting
ECs reportedly secrete a small amount of pro-vWF via a canonical constitutive secretory pathway which is susceptible to protein synthesis inhibition. 39 Constitutive-like (basal or spontaneous) secretion of vWF is thought to occur from storage granules in absence of agonist stimulation. 39, 40 Thus, our studies support the contention that the majority of the vWF secreted from unstimulated ECs does not occur via the classical constitutive secretory pathway, but rather via basal (constitutive-like) release from a post-Golgi storage compartment, 40 presumably
WPBs. 39 Based on the results of the present study, we speculate that the low level but otherwise normal appearing low, intermediate, and high molecular weight plasma vWF multimers observed in Gα12 -/-mice is due to the lack of WPB priming and vWF secretion via Gα12-αSNAP dependent activation of exocytosis.
As basal vWF secretion was reportedly calcium-independent, 41 Gα12-mediated basal vWF secretion is also likely to occur independent of an increase in intracellular [Ca 2+ ]. In contrast, endothelial Gαq/11 signaling may be important for potentiating vWF release in response to thrombin via Ca 2+ -dependent activation of α SNAP. 42 With regards to the molecular mechanism by which α -SNAP is involved in fusion and in exocytosis, it is known that the binding of α -SNAP and stimulation of NSF ATP-ase activity is Ca 2+ -dependent, 42 that α -SNAP can be activated by post-translational modification, 43 and that S-nitrosylation of NSF inhibits WPB exocytosis. 17 Based on the observed reduction in basal vWF secretion in Gα12-depleted ECs, we speculate that Gα12 facilitates the final step of secretion by potentiating the binding of 1 8 NSF to α -SNAP, thereby increasing NSF ATP-ase activity and fusion of WPBs with the plasma membrane. Gα12 activation by PAR1 at the plasma membrane appears to also play a role by promoting delivery of WPBs to the plasma membrane, while Ca 2+ signaling liberated by the Gαq/11-dependent pathway may further activate α -SNAP activity (Figure 7) . In summary, absence of Gα12 in endothelial cells renders them unable to maintain receptor-independent basal vWF secretion or integrate on-demand signals coming from the coagulation cascade (i.e.
thrombin stimulation) whereas Gαq/11 deficiency resulted in moderate but significant attenuation of thrombin-mediated vWF secretion.
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